<DOC>
	<DOCNO>NCT02685033</DOCNO>
	<brief_summary>This clinical study single-center , randomize , open-label , active-controlled , parallel-group study compare dalbavancin standard care ( SOC ) therapy osteomyelitis .</brief_summary>
	<brief_title>Study Safety Efficacy Dalbavancin Versus Active Comparator Adult Subjects With Osteomyelitis</brief_title>
	<detailed_description />
	<mesh_term>Osteomyelitis</mesh_term>
	<mesh_term>Dalbavancin</mesh_term>
	<mesh_term>Teicoplanin</mesh_term>
	<criteria>A diagnosis osteomyelitis ( first episode ) define : Pain point tenderness upon palpation probe bone Plain radiograph Magnetic resonance imaging ( MRI ) consistent osteomyelitis ( indistinctly marginated edemalike pattern bone marrow hypointensity unenhanced T1weighted sequence , hyperintensity fatsaturated T2weighted Short tau inversion recovery ( STIR ) sequence and/or abnormal enhancement gadoliniumenhanced fatsaturated T2weighted sequence , without visible periostitis cortical bone destruction ) OR Grampositive cocci document baseline Gramstain bone specimen Elevated Creactive protein ( CRP ) ( low sensitivity ) upper limit normal ( ULN ) ( reference range low sensitivity CRP 310 mg/L ) Subjects must willing able , discharged hospital , return hospital designate clinic schedule visit , treatment , laboratory test , outpatient procedure require protocol . Treatment investigational drug within 30 day precede first dose investigational product . Receipt &gt; 24 hour potentially effective IV antibacterial therapy osteomyelitis within 96 hour randomization , unless pathogen isolate document Methicillinresistant Staphylococcus aureus ( MRSA ) resistant administer antibiotic . A prior episode osteomyelitis , fail course therapy osteomyelitis . Infection associate burn wound , sacral decubitus ulcer , multiple site osteomyelitis . Septic arthritis noncontiguous osteomyelitis , diagnose isolation pathogen synovial fluid culture . Immunosuppression/immune deficiency Evidence Gramnegative bacteria Gram stain absence Grampositive organism . Gramnegative bacteremia Patients concomitant endocarditis , necrotizing fasciitis , prosthetic material site infection time study initiation . Infection due organism know prior study entry susceptible dalbavancin ( dalbavancin mean inhibitory concentration [ MIC ] &gt; 0.12 μg/mL ) vancomycin ( vancomycin MIC &gt; 2 μg/mL ) . Concomitant systemic antibacterial therapy Grampositive infection ( eg , rifampin , gentamicin ) . Known suspected hypersensitivity glycopeptide antibiotic . Patients rapidly fatal illness , expect survive 3 month . Pregnant nursing female ; positive urine ( serum ) pregnancy test Screening ( premenopausal female ) admission ( prior dosing ) Sexually active female childbearing potential unwilling unable use acceptable method contraception least first dose study drug last pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Osteomyelitis</keyword>
	<keyword>dalbavancin</keyword>
	<keyword>antibiotic</keyword>
</DOC>